Skip to main content

Table 1 Univariable Cox model analyses for disease-free survival of patients with NSCLC receiving neoadjuvant immunochemotherapy

From: “Major pathologic response” in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy

 

Number of patients

Univariable

HR (95%CI)

P value

Age (continuous)

53

1.04 (0.98–1.10)

0.217

Gender

  

0.724

Male

47

ref.

 

Female

6

1.26 (0.36–4.45)

 

Histology subtype

  

0.984

LUSQ

35

ref.

 

Non-LUSQ

18

0.99 (0.41–2.37)

 

PT-MPR

  

0.047

PT-MPR(-)

22

ref.

 

PT-MPR(+)

31

0.43 (0.18–0.99)

 

mLN-RVT

  

0.039

mLN-RVT 11–100%

19

ref.

 

mLN-RVT 0%

28

0.32 (0.13–0.78)

 

mLN-RVT 1–10%

6

0.42 (0.11–1.61)

 

mLN-MPR

  

0.011

mLN-MPR(-)

19

ref.

 

mLN-MPR(+)

34

0.34 (0.14–0.78)

 

mLN-MPR/PT-MPR response pattern

 

0.030

mLN-MPR(-)/PT-MPR(-)

10

ref.

 

mLN-MPR(-)/PT-MPR(+)

9

0.45 (0.12–1.66)

 

mLN-MPR(+)/PT-MPR(-)

12

0.35 (0.11–1.08)

 

mLN-MPR(+)/PT-MPR(+)

22

0.21 (0.08–0.61)

 

pN stage

  

0.036

N2-N1

25

ref.

 

N0

28

0.40 (0.17–0.94)

 

pN stage/PT-MPR response pattern

  

0.117

pN2-N1/PT-MPR(-)

13

ref.

 

pN2-N1/PT-MPR(+)

12

0.73 (0.24–2.21)

 

pN0/PT-MPR(-)

9

0.70 (0.22–2.28)

 

pN0/PT-MPR(+)

19

0.24 (0.07–0.76)

 

Adjuvant treatment

  

0.178

No

13

ref.

 

Yes

40

0.55 (0.23–1.32)

 
  1. MPR, major pathologic response; mLN, metastatic lymph node; RVT, residual viable tumor; PT, primary tumor; LUSQ, lung squamous carcinoma